CoLucid Pharmaceuticals Inc (CLCD) : Bvf Incil added new position in CoLucid Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 763,300 shares of CoLucid Pharmaceuticals Inc which is valued at $26,868,160 , the company said in a statement filed on Nov 14, 2016 with the SEC.CoLucid Pharmaceuticals Inc makes up approximately 4.42% of Bvf Incil’s portfolio.
Other Hedge Funds, Including , Parametric Portfolio Associates added CLCD to its portfolio by purchasing 37,612 company shares during the most recent quarter which is valued at $1,419,853. Mpm Asset Management sold out all of its stake in CLCD during the most recent quarter. The investment firm sold 21,806 shares of CLCD which is valued $799,190.Blackrock Fund Advisors boosted its stake in CLCD in the latest quarter, The investment management firm added 68 additional shares and now holds a total of 8,565 shares of CoLucid Pharmaceuticals Inc which is valued at $249,670.Blackrock Investment Management reduced its stake in CLCD by selling 43 shares or 7.6% in the most recent quarter. The Hedge Fund company now holds 523 shares of CLCD which is valued at $15,245. Sg Americas Securities sold out all of its stake in CLCD during the most recent quarter. The investment firm sold 56,769 shares of CLCD which is valued $1,654,816.
CoLucid Pharmaceuticals Inc closed down -1 points or -2.67% at $36.45 with 1,60,342 shares getting traded on Monday. Post opening the session at $37.4, the shares hit an intraday low of $35.5317 and an intraday high of $38.5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, CoLucid Pharmaceuticals Inc reported $-0.59 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Nov 10, 2015. Analyst had a consensus of $-0.63.During the same quarter in the previous year, the company posted $-4.97 EPS.
Many Wall Street Analysts have commented on CoLucid Pharmaceuticals Inc. Company shares were Reiterated by Stifel on Oct 24, 2016 to “Buy”, Firm has raised the Price Target to $ 40 from a previous price target of $30 .Company shares were Reiterated by Stifel on Sep 19, 2016 to “Buy”, Firm has raised the Price Target to $ 30 from a previous price target of $27 .
CoLucid Pharmaceuticals Inc. is a United States-based clinical-stage biopharmaceutical company that develops a product candidate Lasmiditan for the treatment of central nervous system (CNS) disorders. The Company develops oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. Its Lasmiditan is used for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. The Company has completed seven clinical studies for Lasmiditan including a TQTc study and a Phase IIb study treating a single migraine attack in around 391 patients.